Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Dabrafenib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,696Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Tafinlar

    02 10Tafinlar/Mekinist

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Tafinlar/Mekinist

    Dabrafenib, Trametinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib, Trametinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,542

    2019 Revenue in Millions : 1,338

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tafinlar/Mekinist

    Dabrafenib, Trametinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib, Trametinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,693

    2020 Revenue in Millions : 1,542

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tafinlar/Mekinist

    Dabrafenib, Trametinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib, Trametinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 1,770

    2021 Revenue in Millions : 1,693

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tafinlar/Mekinist

    Dabrafenib, Trametinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib, Trametinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,922

    2022 Revenue in Millions : 1,770

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Tafinlar/Mekinist

    Dabrafenib, Trametinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib, Trametinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 2,058

    2023 Revenue in Millions : 1,922

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tafinlar

    Dabrafenib Mesylate

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar

    United Kingdom
    arrow
    IPPE
    Not Confirmed

    GlaxoSmithKline

    Dabrafenib Mesylate

    Main Therapeutic Indication : Oncology

    Currency : USD

    2014 Revenue in Millions : 743.80%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tafinlar/Mekinist

    Dabrafenib Mesylate

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib Mesylate

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 0

    2014 Revenue in Millions : 453

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Tafinlar/Mekinist

    Dabrafenib Mesylate

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib Mesylate

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 672

    2015 Revenue in Millions : 453

    Growth (%) : 48

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Tafinlar/Mekinist

    Dabrafenib Mesylate

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib Mesylate

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 873

    2016 Revenue in Millions : 672

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Tafinlar/Mekinist

    Dabrafenib Mesylate

    arrow
    IPPE
    Not Confirmed

    Brand Name : Tafinlar/Mekinist

    Switzerland
    arrow
    IPPE
    Not Confirmed

    Novartis

    Dabrafenib Mesylate

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 1,155

    2017 Revenue in Millions : 873

    Growth (%) : 32%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.